Online citations, reference lists, and bibliographies.
← Back to Search

PET Scan Imaging In Oncology.

G. Jerusalem, R. Hustinx, Y. Beguin, G. Fillet
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
With the emergence of positron emission tomography (PET) from research laboratories into routine clinical use, it is important to redefine the most appropriate use of each imaging technique. The aim of this review article is to show the potential of PET in oncology. We discuss the most promising indications and the perspectives for the future. We will also point out the shortcomings and the important questions to be answered before fully considering PET as a necessary tool in the day-to-day practice of oncology. Although many studies have documented the high accuracy of 18F-FDG PET for the detection and staging of malignant tumours and for the monitoring of therapy results in these patients, it is very important to assess the impact of the technique on patient outcome and to show cost-effectiveness from the societal viewpoint.
This paper references
10.3816/CLM.2000.N.007
Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.
L. Kostakoglu (2000)
10.1056/NEJM200007273430404
Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
R. Pieterman (2000)
10.1148/RADIOL.2243011362
Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
K. Kinkel (2002)
10.1016/S0959-8049(02)00413-6
PET for in vivo pharmacokinetic and pharmacodynamic measurements.
N. Gupta (2002)
10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.0.CO;2-#
Systematic review of the diagnostic accuracy of 18F‐fluorodeoxyglucose positron emission tomography in melanoma patients
G. Sophie Mijnhout (2001)
10.1016/S1526-9655(11)70192-0
Commentary on “Positron Emission Tomography in Lymphoma: Comparison with Computed Tomography and Gallium-67 Single Photon Emission Computed Tomography Imaging”
G. Jerusalem (2000)
10.1093/ANNONC/MDF664
The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
G. Jerusalem (2002)
10.1001/JAMA.285.7.914
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.
M. Gould (2001)
10.1016/S0959-8049(02)00385-4
Assessment of the technology for functional imaging in cancer.
G. Laking (2002)
10.1148/RADIOLOGY.199.3.8638000
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
P. Shreve (1996)
10.1016/S0140-6736(02)08352-6
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial
H. Tinteren (2002)
10.1200/JCO.1999.17.11.3457
Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
K. Ganjoo (1999)
10.1054/bjoc.2000.1496
Application of positron emission tomography imaging to cancer screening
S. Yasuda (2000)
10.1097/00000658-199803000-00001
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.
F. Flanagan (1998)
10.1200/JCO.1999.17.5.1508
Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
J. Wagner (1999)
10.1200/JCO.1998.16.6.2113
Analytical decision model for the cost-effective management of solitary pulmonary nodules.
S. Gambhir (1998)
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.
C. Hoekstra (2002)
10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
V. Ahuja (1998)
10.1002/cncr.10494
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma
C. Kollmannsberger (2002)
18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
G. Laking (2001)
10.1007/s002680010182
Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations
A. Sendler (2000)
10.1097/00004728-197904000-00061
Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.
Brian M. Gallagher (1978)
10.1016/S0959-8049(02)00388-X
Functional MRI for anticancer therapy assessment.
A. Padhani (2002)
10.1002/(SICI)1097-0142(19990701)86:1<114::AID-CNCR16>3.0.CO;2-E
Occult primary tumors of the head and neck
K. Greven (1999)
10.1182/BLOOD.V94.2.429.414K26_429_433
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
G. Jerusalem (1999)
10.1093/ANNONC/MDG011
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
G. Jerusalem (2003)
10.1023/A:1008327127033
The role of positron emission tomography (PET) in the management of lymphoma patients.
P. Zinzani (1999)
10.1023/A:1011169332265
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).
G. Jerusalem (2001)
10.1016/S0360-3016(01)01642-X
Can positron emission tomography improve the quality of care for head-and-neck cancer patients?
N. Schechter (2001)
10.1016/S0959-8049(02)00412-4
Gamma camera imaging in malignancy.
J. W. Evans (2002)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1016/S1010-7940(01)00827-2
PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
A. Poncelet (2001)
10.1016/S0959-8049(02)00383-0
Functional ultrasound methods in oncological imaging.
M. Blomley (2002)
10.1016/S0959-8049(02)00386-6
Functional computed tomography in oncology.
K. Miles (2002)
10.1016/S0959-8049(02)00389-1
Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma.
J. Griffiths (2002)
10.1177/028418519103200302
Clinical Value of Pet with 18F-Fluorodeoxyglucose and L-Methyl-11C-Methionine for Diagnosis of Recurrent Brain Tumor and Radiation Injury
T. Ogawa (1991)
10.1097/00006231-200210000-00007
FDG-PET improves the management of patients with suspected recurrence of colorectal cancer
M. Simo (2002)
10.1016/S0959-8049(02)00384-2
CT colonography (virtual colonoscopy) for the detection of colorectal polyps and neoplasms. current status and future developments.
T. Gluecker (2002)
10.1200/JCO.2001.19.2.414
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
K. Spaepen (2001)
10.1016/S0959-8049(02)00390-8
PET imaging of gene expression.
R. Blasberg (2002)
10.1002/(SICI)1097-0142(19980315)82:6<1160::AID-CNCR22>3.0.CO;2-3
Detection of unknown occult primary tumors using positron emission tomography
A. Kole (1998)
Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
S. Gambhir (1996)
10.1023/A:1008357126404
18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.
M. de Wit (2001)
Evaluation thérapeutique précoce par tomographie à émission de positons
G. Jerusalem (2000)
10.1097/00005537-200009000-00016
Positron Emission Tomography With Fluorodeoxyglucose for Suspected Head and Neck Tumor Recurrence in the Symptomatic Patient
M. Lonneux (2000)
FDG PET detection of unknown primary tumors.
K. H. Bohuslavizki (2000)
10.1016/S0001-2998(96)80006-7
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.
G. Cook (1996)
10.1182/BLOOD.V98.10.2930
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
M. Weihrauch (2001)
10.1097/00000658-200103000-00001
Survival of Patients Evaluated by FDG-PET Before Hepatic Resection for Metastatic Colorectal Carcinoma: A Prospective Database Study
S. Strasberg (2001)
10.1200/JCO.20.2.388
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
T. Ruers (2002)
10.1016/S0959-8049(99)00077-5
18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
U. Lassen (1999)
10.1200/JCO.1999.17.10.3201
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
J. Vansteenkiste (1999)
10.1200/JCO.2001.19.17.3740
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
M. de Santis (2001)
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
G. Jerusalem (2000)
10.1097/00000658-200111000-00014
Value of 18-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients With Cystic Tumors of the Pancreas
C. Sperti (2001)
10.1023/A:1013107732572
Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management.
D. Rades (2001)
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.
R. Huebner (2000)
10.1200/JCO.2001.19.10.2674
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.
K. Acland (2001)
10.1148/RADIOLOGY.213.2.R99NV46530
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.
B. Dwamena (1999)
10.1093/JNCI/88.17.1204
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
N. Avril (1996)
10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO;2-0
Positron emission tomography scanning in malignant melanoma
Douglas S. Tyler (2000)
10.1148/RADIOLOGY.210.1.R99JA48177
Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
O. S. Aassar (1999)



This paper is referenced by
10.1089/CBR.2005.20.310
Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection.
P. Kok (2005)
Prognostic value of 18 F-fluorodeoxyglucose-uptake in locally advanced soft tissue sarcomas treated with regional chemotherapy
K. Thijssens (2006)
Computed Tomography and Pos i t ion Emis s ion Tomography in Rad ia t ion Onco logy
()
10.1016/B978-012744482-6.50006-5
CHAPTER 3 – Evolution of Clinical Emission Tomography
A. Brill (2004)
10.1023/B:BMMD.0000031747.05317.81
Molecular Imaging Applications in Nanomedicine
K. C. Li (2004)
10.1016/J.MPMED.2007.10.011
Imaging in cancer
A. Rembielak (2008)
10.1097/00004728-200607000-00022
Role of 18F-FDG PET/CT in Staging and Follow-up of Lymphoma in Pediatric and Young Adult Patients
E. Miller (2006)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1007/s00259-003-1444-2
Performance evaluation of the new whole-body PET/CT scanner: Discovery ST
V. Bettinardi (2003)
10.1177/147323000703500405
Lesion Detectability and Clinical Effectiveness of Dual-head Coincidence Gamma Camera Imaging in Comparison with Dedicated PET Systems in Tumour Patients
Y. Narịn (2007)
10.1016/B978-0-323-07954-9.00002-5
Chapter 2 – General Characteristics of the Spine
G. Cramer (2014)
Identifying response to therapy in longitudinal PET imaging studies
M. Phillips (2014)
10.1007/978-3-662-44169-5_4
Nuclear medicine imaging.
D. Ng (2015)
10.1111/j.1525-1438.2007.00943.x
Follow-up strategies in gynecological oncology: searching appropriateness
P. Zola (2007)
10.1007/978-3-540-85516-3_18
imaging in oncology
Agata Rembielak (2015)
10.1016/J.EJSO.2006.10.020
The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
E. Pelosi (2007)
Physical characterization of a PET / CT scanner
Maria Inês Silva (2008)
10.1103/PhysRevA.70.032720
Many-body theory of positron-atom interactions
G. Gribakin (2004)
10.1016/j.biomaterials.2010.11.059
64Cu loaded liposomes as positron emission tomography imaging agents.
A. L. Petersen (2011)
Screening of 14C-polyamines in the AT3B-1 rat prostate tumor model: the search for a new PET prostate imaging agent.
S. Palakurthi (2007)
10.1016/B978-0-7234-3496-2.00019-1
Mediastinal and aortic disease
D. Hansell (2010)
10.1158/1078-0432.CCR-06-0383
Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer
O. Couturier (2006)
valuation of Therapy for Lymphoma
U. Jerusalem (2005)
10.1158/0008-5472.CAN-08-3118
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
A. Memon (2009)
10.1097/RLU.0b013e3181b7daf6
PET scanning used for monitoring treatment response in Mycobacterium avium complex infection mimicking malignancy.
J. Drijkoningen (2009)
Partial pressure of oxygen in the human body: a general review.
E. Ortiz-Prado (2019)
10.1109/MEMB.2004.1337947
Positron emission tomography in molecular imaging
M.G. Pomper (2004)
10.1007/s00726-005-0199-4
The usefulness of radiotracers to make the body biochemically transparent
B. Johannsen (2005)
10.2214/AJR.184.4.01841172
Persistent foreign body reaction around inguinal mesh prostheses: a potential pitfall of FDG PET.
N. Aide (2005)
10.1007/s11307-005-0011-6
Uptake of a Fluorescent Deoxyglucose Analog (2-NBDG) in Tumor Cells
R. G. O’Neil (2005)
10.1053/J.SEMNUCLMED.2005.02.004
Evaluation of therapy for lymphoma.
G. Jerusalem (2005)
10.1097/01.rlu.0000162604.51925.5e
Technetium-99m Diphosphonate Imaging of Psammocarcinoma of Probable Ovarian Origin: Case Report and Literature Review
A. I. Radin (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar